Determinants of antibody response after recombinant gp160 boosting in vaccinia-naive volunteers primed with gp160-recombinant vaccinia virus. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Clinical Trials Network.

@article{Graham1994DeterminantsOA,
  title={Determinants of antibody response after recombinant gp160 boosting in vaccinia-naive volunteers primed with gp160-recombinant vaccinia virus. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Clinical Trials Network.},
  author={B. Graham and G. Gorse and D. Schwartz and M. Keefer and M. Mcelrath and T. Matthews and P. Wright and R. Belshe and M. Clements and R. Dolin},
  journal={The Journal of infectious diseases},
  year={1994},
  volume={170 4},
  pages={
          782-6
        }
}
Priming with a live recombinant vector followed by subunit boosting is a promising strategy for human immunodeficiency virus (HIV) immunization. Twenty-nine vaccinia-naive volunteers were primed with gp160-recombinant vaccinia virus (HIVAC-1e) and boosted with recombinant (r) gp160 to define factors associated with the magnitude and specificity of antibody response after booster immunization. A longer interval between inoculation and boost, two inoculations of HIVAC-1e with lesion formation… Expand
The role of antibodies in HIV vaccines.
...
1
2
3
4
...

References

SHOWING 1-10 OF 11 REFERENCES
Expression of AIDS virus envelope gene in recombinant vaccinia viruses
...
1
2
...